# Managed Access Programs for INC424, Ruxolitinib

> **NCT04745637** · — · AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Primary Myelofibrosis (PMF)
- Post Polycythemia Myelofibrosis (PPV MF)
- Thrombocythemia Myelofibrosis (PET-MF)
- Severe/Very Severe COVID-19 Illness
- Polycythemia Vera (PV)
- Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)
- Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04745637
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745637, "Managed Access Programs for INC424, Ruxolitinib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04745637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*